ROIV

+ Watchlist + Portfolio

Roivant Sciences Ltd.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $35.50
52-Week Range: $15.25 – $42.50
Market Cap: $25.80B
P/E (TTM): —
EPS (TTM): -0.53
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 6.10
PEG Ratio: —
Return on Equity: -8.52%
Return on Assets: -16.48%
Gross Margin: 0.00%
Operating Margin: -25408.11%
Profit Margin: 0.00%
Current Ratio: 16.72
Debt/Equity: 0.02
Total Debt: $107.15M
Free Cash Flow: $-1.13B
Revenue Growth: -33.50%
Earnings Growth: —
Enterprise Value: $22.76B

ROIV Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$31.53M	$32.71M	$29.05M	$8.26M
Cost of Revenue	$3.03M	$1.60M	$911.00K	$1.28M
Gross Profit	$28.50M	$31.11M	$28.14M	$6.97M
Research & Development	$454.06M	$439.91M	$550.41M	$681.81M
Selling, General & Admin	$383.45M	$416.13M	$591.41M	$610.47M
Operating Expenses	$837.51M	$856.04M	$1.14B	$1.29B
Operating Income	-$809.01M	-$824.93M	-$1.11B	-$1.29B
EBITDA	-$790.16M	-$802.89M	-$1.10B	-$1.28B
Pretax Income	-$884.99M	$4.57B	-$681.59M	-$264.58M
Income Tax	$4.08M	$21.50M	$48.17M	$133.33M
Net Income	-$1.01B	$4.35B	-$171.98M	-$299.77M
Diluted EPS	-1.42	5.23	-0.24	-0.54
Diluted Shares	712.79M	831.05M	725.40M	693.86M

ROIV Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$1.68B	$6.49B	$2.72B	$1.42B
Receivables	$37.64M	$82.81M	$0.00	$770.24M
Inventory	$2.76M	$35.25M	—	—
Current Assets	$1.80B	$6.73B	$5.00B	$5.17B
Total Assets	$2.39B	$7.22B	$5.44B	$5.71B
Current Liabilities	$272.45M	$266.76M	$149.41M	$281.24M
Long-Term Debt	$375.51M	$430.59M	—	—
Total Debt	$481.40M	$53.99M	$100.17M	$107.44M
Total Liabilities	$782.02M	$773.95M	$249.74M	$416.27M
Retained Earnings	-$3.77B	$576.17M	$116.06M	-$501.81M
Shareholders' Equity	$1.16B	$5.97B	$4.69B	$4.53B
Working Capital	$1.53B	$6.47B	$4.85B	$4.89B

ROIV Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$843.39M	-$765.27M	-$839.45M	-$750.35M
Capital Expenditure	-$12.69M	-$1.38M	-$4.60M	-$8.21M
Free Cash Flow	-$856.08M	-$766.65M	-$844.05M	-$758.56M
Depreciation & Amortisation	$18.86M	$22.04M	$14.07M	$3.35M
Stock-Based Compensation	$217.78M	$199.63M	$289.03M	$346.17M
Investing Cash Flow	-$44.27M	$5.20B	-$1.77B	-$682.33M
Financing Cash Flow	$499.46M	$419.36M	-$1.22B	$134.24M
Share Repurchases	$0.00	$0.00	-$1.29B	-$319.50M
Net Change in Cash	-$388.20M	$4.86B	-$3.83B	-$1.30B

ROIV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$7.57M	$2.17M	$1.57M	$2.00M	$2.52M	$1.44M
Cost of Revenue	$205.00K	$154.00K	$111.00K	$700.00K	$320.00K	$284.00K
Gross Profit	$7.37M	$2.02M	$1.46M	$1.30M	$2.20M	$1.16M
Research & Development	$145.24M	$152.92M	$164.57M	$165.38M	$198.94M	$202.02M
Selling, General & Admin	$147.09M	$134.02M	$143.13M	$175.07M	$158.25M	$165.53M
Operating Expenses	$292.33M	$286.94M	$307.69M	$340.45M	$357.19M	$367.54M
Operating Income	-$284.96M	-$284.92M	-$306.23M	-$339.15M	-$355.00M	-$366.38M
EBITDA	-$283.54M	-$283.82M	-$305.31M	-$338.46M	-$354.36M	-$365.79M
Pretax Income	-$203.05M	-$269.26M	-$159.04M	-$290.37M	$454.10M	-$294.56M
Income Tax	$49.32M	$4.65M	$7.00M	$23.33M	$98.35M	-$3.96M
Net Income	-$206.47M	-$223.35M	-$113.52M	-$265.89M	$302.99M	-$189.84M
Diluted EPS	-0.29	-0.33	-0.17	-0.38	0.28	-0.26
Diluted Shares	707.30M	680.29M	680.95M	696.86M	812.29M	720.78M

ROIV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.72B	$1.24B	$1.24B	$1.48B	$1.42B	$1.25B
Receivables	$0.00	—	—	—	$770.24M	$771.63M
Current Assets	$5.00B	$4.62B	$4.51B	$4.66B	$5.17B	$4.74B
Total Assets	$5.44B	$5.03B	$5.06B	$5.23B	$5.71B	$5.31B
Current Liabilities	$149.41M	$113.87M	$133.86M	$151.96M	$281.24M	$283.60M
Total Debt	$100.17M	$99.69M	$98.85M	$108.94M	$107.44M	$107.15M
Total Liabilities	$249.74M	$216.70M	$257.14M	$251.14M	$416.27M	$384.62M
Retained Earnings	$116.06M	-$315.59M	-$429.11M	-$695.00M	-$501.81M	-$900.35M
Shareholders' Equity	$4.69B	$4.35B	$4.36B	$4.27B	$4.53B	$4.23B
Working Capital	$4.85B	$4.50B	$4.38B	$4.51B	$4.89B	$4.46B

ROIV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$172.56M	-$204.38M	-$185.66M	-$196.48M	-$163.82M	-$270.50M
Capital Expenditure	-$811.00K	-$4.04M	-$7.85M	—	-$1.26M	-$419.00K
Free Cash Flow	-$173.38M	-$208.42M	-$193.51M	-$191.55M	-$165.08M	-$270.92M
Depreciation & Amortisation	$1.43M	$1.10M	$921.00K	$691.00K	$638.00K	$600.00K
Stock-Based Compensation	$83.49M	$82.18M	$81.82M	$105.00M	$77.17M	$83.34M
Investing Cash Flow	$1.07B	-$1.09B	$120.42M	$109.47M	$173.49M	$281.26M
Financing Cash Flow	-$177.15M	-$187.77M	$62.59M	$328.19M	-$68.78M	-$181.51M
Share Repurchases	-$295.44M	-$208.29M	$0.00	$0.00	-$111.21M	-$206.73M
Net Change in Cash	$724.48M	-$1.48B	-$2.65M	$241.18M	-$59.10M	-$170.75M

Market Snapshot

About

Roivant Sciences is a biopharmaceutical company focused on applying technology and data science to drug development. The company builds subsidiary biotech and healthcare technology companies (Vants) to develop and commercialize medicines and technologies. Roivant aims to improve the efficiency and success rate of bringing innovative therapies to patients through its unique organizational model.